Leerink Partners Upgrades Tandem Diabetes Care to Outperform, Raises Price Target to $45
Portfolio Pulse from Benzinga Newsdesk
Leerink Partners analyst Mike Kratky upgraded Tandem Diabetes Care (TNDM) from Market Perform to Outperform and increased the price target from $34 to $45.
April 25, 2024 | 1:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tandem Diabetes Care was upgraded by Leerink Partners from Market Perform to Outperform with a price target increase from $34 to $45.
Upgrades by analysts, especially with a significant increase in price target, typically lead to positive short-term price movements as they reflect a positive change in the company's outlook. The upgrade from Market Perform to Outperform suggests a strong confidence in Tandem Diabetes Care's future performance, potentially attracting more investors.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100